About
Discover Our Story:
About Us
We are a pioneering biotechnology company established in 2001. Our technology uses proprietary small molecules and tumor-sensitizing technology. We have developed a groundbreaking technology to tackle cancer with technology. Our approach involves the prior activation of the apoptosis pathway of tumor technology, which targets and sensitizes both cancer stem cells and low-responsive resistant cells concurrently.
By doing so, our AAAPT technology enables doctors to make chemotherapy more effective by combining tumor regression and reducing cardio toxicity. Our innovative solutions hold great promise in revolutionizing cancer treatment and improving the quality of life of cancer patients around the world.
Our mission
To pioneer innovative biotechnological solutions that revolutionize cancer treatment, empowering healthcare professionals to effectively combat cancer while enhancing the quality of life for patients worldwide.
Our Vision
At SEMCO, we envision a future where cancer is no longer a life-threatening disease but a manageable condition. Through our groundbreaking AAAPT technology, we strive to transform the landscape of cancer treatment, offering hope, healing, and improved outcomes for patients globally.
Our Objectives
- Work with top oncologists and research institutions to validate our technology through clinical trials.
- Make our cancer treatments accessible globally, ensuring they're affordable for everyone.
- Encourage innovation and scientific excellence at SEMCO, nurturing talent to advance biotechnology.
- Lobby for regulatory support to speed up approval for new cancer therapies.
- Educate healthcare professionals and the public about the benefits of our AAAPT technology in chemotherapy.